Zacks Small Cap Expects Increased Earnings for VolitionRx

VolitionRx Limited (NYSE:VNRX) – Investment analysts at Zacks Small Cap upped their FY2024 EPS estimates for VolitionRx in a note issued to investors on Wednesday, December 4th. Zacks Small Cap analyst S. Ralston now expects that the company will earn ($0.28) per share for the year, up from their prior forecast of ($0.29). The consensus estimate for VolitionRx’s current full-year earnings is ($0.31) per share. Zacks Small Cap also issued estimates for VolitionRx’s Q4 2024 earnings at ($0.06) EPS.

Several other research firms have also recently issued reports on VNRX. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. StockNews.com initiated coverage on shares of VolitionRx in a research report on Friday. They issued a “sell” rating on the stock.

VolitionRx Trading Up 9.9 %

VolitionRx stock opened at $0.63 on Monday. The stock has a market cap of $58.29 million, a P/E ratio of -1.75 and a beta of 1.17. The company has a 50-day moving average price of $0.69 and a 200 day moving average price of $0.67. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.23.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.